Emma B Holliday1, Pamela K Allen2, Hesham Elhalawani1, Omar Abdel-Rahman3. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3. Clinical Oncology Department, Faculty of Medicine, Ain shams University, Cairo, Egypt.
Abstract
BACKGROUND: Some patients undergo a non-operative approach to localized rectal adenocarcinoma either because they decline surgery or because their medical comorbidities preclude surgical intervention. Published studies reporting excellent outcomes with a "wait-and-see" approach have been small and highly-selected. We aimed to analyze survival outcomes and prognostic factors for patients with localized rectal adenocarcinoma in the National Cancer Database (NCDB) undergoing definitive radiation without surgical intervention. METHODS: The NCDB was queried for patients with non-metastatic rectal adenocarcinoma treated with definitive radiotherapy who did not undergo a surgical resection either because the patient refused surgery, surgery was medically contraindicated, or surgery was otherwise unplanned. Patient, tumor and treatment-related characteristics were compared between those treated with 45-50.3 Gray (Gy), 50.4-54 Gy and >54 Gy. Survivals were compared using the Log-Rank test. Univariate and multivariate Cox regression analyses were performed. Survivals were then compared utilizing a robust inverse-probability-weighted regression adjustment method with nearest-neighbor matching. RESULTS: Eight thousand four hundred and eight patients were included for analysis. After case-matching and adjusting for significant prognostic factors, patients receiving 50.4-54 Gy had a significantly longer median, 1- and 5-year overall survival (OS) (49.4 months, 85.8%, 44.7%) compared with patients receiving 45-50.3 or >54 Gy (37.2 months, 79.2%, 38.4% and 34.2 months, 84.5%, 35.3%, respectively; Log rank P value <0.0001). CONCLUSIONS: In an unselected group of patients treated at NCDB-participating institutions, survival rates with a non-surgical approach to non-metastatic rectal adenocarcinoma are much lower than those reported in well-selected single-institutional studies. Moderate dose escalation from 50.4-54 Gy was associated with better OS compared with doses <50.4 Gy or >54 Gy after adjusting for significant covariant.
BACKGROUND: Some patients undergo a non-operative approach to localized rectal adenocarcinoma either because they decline surgery or because their medical comorbidities preclude surgical intervention. Published studies reporting excellent outcomes with a "wait-and-see" approach have been small and highly-selected. We aimed to analyze survival outcomes and prognostic factors for patients with localized rectal adenocarcinoma in the National Cancer Database (NCDB) undergoing definitive radiation without surgical intervention. METHODS: The NCDB was queried for patients with non-metastatic rectal adenocarcinoma treated with definitive radiotherapy who did not undergo a surgical resection either because the patient refused surgery, surgery was medically contraindicated, or surgery was otherwise unplanned. Patient, tumor and treatment-related characteristics were compared between those treated with 45-50.3 Gray (Gy), 50.4-54 Gy and >54 Gy. Survivals were compared using the Log-Rank test. Univariate and multivariate Cox regression analyses were performed. Survivals were then compared utilizing a robust inverse-probability-weighted regression adjustment method with nearest-neighbor matching. RESULTS: Eight thousand four hundred and eight patients were included for analysis. After case-matching and adjusting for significant prognostic factors, patients receiving 50.4-54 Gy had a significantly longer median, 1- and 5-year overall survival (OS) (49.4 months, 85.8%, 44.7%) compared with patients receiving 45-50.3 or >54 Gy (37.2 months, 79.2%, 38.4% and 34.2 months, 84.5%, 35.3%, respectively; Log rank P value <0.0001). CONCLUSIONS: In an unselected group of patients treated at NCDB-participating institutions, survival rates with a non-surgical approach to non-metastatic rectal adenocarcinoma are much lower than those reported in well-selected single-institutional studies. Moderate dose escalation from 50.4-54 Gy was associated with better OS compared with doses <50.4 Gy or >54 Gy after adjusting for significant covariant.
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: Michael J O'Connell; Linda H Colangelo; Robert W Beart; Nicholas J Petrelli; Carmen J Allegra; Saima Sharif; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; David S Parda; Mohammed Mohiuddin; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini S Soori; Janice Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Timothy F Wozniak; Mark S Roh; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: Milou H Martens; Monique Maas; Luc A Heijnen; Doenja M J Lambregts; Jeroen W A Leijtens; Laurents P S Stassen; Stephanie O Breukink; Christiaan Hoff; Eric J Belgers; Jarno Melenhorst; Rob Jansen; Jeroen Buijsen; Ton G M Hoofwijk; Regina G H Beets-Tan; Geerard L Beets Journal: J Natl Cancer Inst Date: 2016-08-10 Impact factor: 13.506
Authors: Lisette M Wiltink; Corrie A M Marijnen; Elma Meershoek-Klein Kranenbarg; Cornelis J H van de Velde; Remi A Nout Journal: Acta Oncol Date: 2015-09-25 Impact factor: 4.089
Authors: Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: J Joshua Smith; Oliver S Chow; Marc J Gollub; Garrett M Nash; Larissa K Temple; Martin R Weiser; José G Guillem; Philip B Paty; Karin Avila; Julio Garcia-Aguilar Journal: BMC Cancer Date: 2015-10-23 Impact factor: 4.430